PDL BioPharma, Inc.
PDLIV
NASDAQ
Recommendation
Prev Close
--
Volume
--
Avg Vol (90D)
--
Market Cap
--
Dividend & Yield
--
52-Week Range
-- - --
P/E (TTM)
--
EPS (TTM)
| 08/31/2020 | 06/30/2020 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -13.08% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -13.08% | |||
| Cost of Revenue | -- | -7.73% | |||
| Gross Profit | -- | -17.96% | |||
| SG&A Expenses | -- | -22.40% | |||
| Depreciation & Amortization | -- | 10.93% | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -- | -19.55% | |||
| Operating Income | -- | 22.51% | |||
| Income Before Tax | -- | 69.71% | |||
| Income Tax Expenses | -- | 92.56% | |||
| Earnings from Continuing Operations | -- | 59.30% | |||
| Earnings from Discontinued Operations | -- | -15,227.46% | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | 23.96% | |||
| Net Income | -- | -57.52% | |||
| EBIT | -- | 22.51% | |||
| EBITDA | -- | 23.03% | |||
| EPS Basic | 0.00% | -67.03% | |||
| Normalized Basic EPS | -- | 17.42% | |||
| EPS Diluted | 0.00% | -65.15% | |||
| Normalized Diluted EPS | -- | 17.42% | |||
| Average Basic Shares Outstanding | -- | -5.69% | |||
| Average Diluted Shares Outstanding | 0.00% | -5.69% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||